Windward Bio prices $175 million Nasdaq IPO
- Windward Bio priced a $175 million Nasdaq IPO, excluding the greenshoe option.
- A concurrent $50 million private placement with Sanofi brings expected gross proceeds from both transactions to $225 million.
- Novo Holdings invested in Windward in January 2025.
- In September 2026, Windward reported positive interim asthma results for WIN378 and initiated Phase 3.
- Windward develops ultra-long-acting antibodies for respiratory and dermatological diseases; lead candidate WIN378 is designed for twice-yearly dosing.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Novo Holdings A/S published the original content used to generate this news brief on November 16, 2026, and is solely responsible for the information contained therein.